Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Radiopharm Theranostics - Entitlement Offer to raise up to $10 million (ASX:RAD)

-- Radiopharm is undertaking a 1 for 3.55 accelerated non-renounceable entitlement offer to raise up to $10 million (before costs) at A$0.14 per New Share -- Provides the Company with runway until ...read more

Radiopharm Theranostics - Prospectus (ASX:RAD)

Accelerated non-renounceable pro rata entitlement offer of 1 New Share for every 3.55 Existing Shares (and 1 New Option for every New Share issued) at an Offer Price of $0.14 to raise up to approxim...read more

Proposed issue of securities - RAD (ASX:RAD)

To view the Proposed issue of securities, download the attached PDF.

Radiopharm Theranostics - Presentation - Pivalate achieves positive Phase 2 data (ASX:RAD)

To view the presentation, download the attached PDF.

Radiopharm Theranostics - Pivalate achieves positive Phase 2 data in brain mets trial (ASX:RAD)

-- F-18 Pivalate PET shows high uptake regardless of origin of primary tumour -- F-18 Pivalate can be used to monitor cerebral metastases -- Patients without previous external beam radiation show ...read more

Radiopharm Theranostics - Suspension from Official Quotation (ASX:RAD)

The securities of Radiopharm Theranostics Limited (‘RAD’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of RAD, pending the release of an announcem...read more

Radiopharm Theranostics - Notice of Annual General Meeting/Proxy Form (ASX:RAD)

To view the notice, download the attached PDF.

Radiopharm Theranostics - Trading Halt (ASX:RAD)

For more information, download the attached PDF.

Radiopharm Theranostics - FDA grants pediatric disease designation for DUNP19-revised (ASX:RAD)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic us...read more

Radiopharm Theranostics - FDA grants rare pediatric disease designation for DUNP19 (ASX:RAD)

-- Further recognition of DUNP19’s potential in a rare disease impacting children -- The RPD designation allows companies to receive a priority review voucher (at the time of marketing author...read more

Radiopharm Theranostics - FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma (ASX:RAD)

Excellent recognition of the potential of DUNP19 to treat a rare bone cancer The FDA designation derives several benefits including tax breaks, user fee exemption and seven years market...read more

Radiopharm Theranostics - Appendix 4E and Preliminary Final Report (ASX:RAD)

To view the Appendix and Preliminary Financial Report, download the attached PDF.

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

HIGHLIGHTS: -- Sublicensing agreement signed with NeoIndicate, LLC (“NeoIndicate”) to a PTPμ-targeted radiopharmaceutical agent, giving Radiopharm the rights to develop an imaging ...read more

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:RAD)

Highlights * Signed Letter of Intent (LOI) with GenesisCare to support Radiopharm’s first Phase 1 trial in Australia * Entered supply agreement with TerraPower for access to Actinium-225, ...read more

Radiopharm Theranostics Licenses UCLA Dual Action Antibody (ASX:RAD)

* LRCC15 expression is produced by cancer cells AND the surrounding tumour microenvironment, but not by healthy normal tissues. * LRRC15 production is very high in aggressive and treatment-resistan...read more

Viewing: 46 - 60 of 104 Previous | Next